Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Cohort Clear all
Completed Phase 2 Interventional Results available

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

NCT00617994
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Fridley, Minnesota • Rochester, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

NCT03410056
View directory record Official record
Conditions
Rheumatoid Arthritis RA
Interventions
Efavaleukin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
Anniston, Alabama • Torrance, California • Lansing, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of E2086 in Healthy Adult Participants

NCT06481488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

NCT03024437
View directory record Official record
Conditions
Metastatic Cancer, Renal Cancer
Interventions
Atezolizumab, Bevacizumab, Entinostat
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

NCT06674941
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

NCT01457781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

NCT01654965
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Tivantinib, Topotecan Hydrochloride
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

Clinical Impact of Cardiac Photon-Counting Detector CT

NCT05240807
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Photon-counting detector computed tomography (PCD-CT)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 29, 2026, 5:51 PM EDT
Recruiting Phase 1 Interventional

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT06419634
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
BMS-986497, Azacitidine, Venetoclax
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 29, 2026, 5:51 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

NCT02844751
View directory record Official record
Conditions
Osteoarthritis
Interventions
[StroMed + platelet rich plasma (PRP)], [PRP] platelet rich plasma
Biological
Lead sponsor
VivaTech International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Grove City, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 29, 2026, 5:51 PM EDT
Enrolling by invitation No phase listed Observational

Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

NCT04234139
View directory record Official record
Conditions
Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection, Liver Diseases, Hepatitis, Alcoholic, Alcohol-Induced Disorders
Interventions
liver transplant
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01118819
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
Clostridium novyi-NT spores
Biological
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT04084951
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Biological · Drug
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05014139
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Interventions
Enfortumab vedotin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

NCT00437957
View directory record Official record
Conditions
Brain Metastases
Interventions
Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 29, 2026, 5:51 PM EDT
Completed No phase listed Observational

Biomarkers to Predict Time to Plasma HIV RNA Rebound

NCT03001128
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Antiretroviral treatment pause
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional Results available

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

NCT03552029
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Milademetan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fairway, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1Phase 2 Interventional

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

NCT02898753
View directory record Official record
Conditions
Pompe Disease
Interventions
VAL-1221, RhGAA
Drug
Lead sponsor
Valerion Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Orange, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

NCT01316237
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-6620, GS-6620 tablet, 450 mg BID, GS-6620 tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Anaheim, California • Los Angeles, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 29, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

NCT03570619
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 29, 2026, 5:51 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection

NCT04817865
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
Diagnostic Test
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Barrington, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 29, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00003567
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 29, 2026, 5:51 PM EDT